Arun Srivastava

List of Publications by Year in Descending Order

123 papers	6,474 citations	45 h-index	79 g-index
128 ext. papers	7,108 ext. citations	6.7 avg, IF	5.81 L-index

#	Paper	IF	Citations
123	AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo. *Gene Therapy*, **2021**, 28, 422-434	4	6
122	Site-specific modifications to AAV8 capsid yields enhanced brain transduction in the neonatal MPS IIIB mouse. *Gene Therapy*, **2021**, 28, 447-455	4	1
121	Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India. *Human Gene Therapy*, **2021**, 32, 451-457	4.8	7
120	Reply to "D" matters in recombinant AAV packaging. *Molecular Therapy*, **2021**, 29, 2628-2630	11.7	0
119	Coagulation factor IX gene transfer to non-human primates using engineered AAV3 capsid and hepatic optimized expression cassette. *Molecular Therapy - Methods and Clinical Development*, **2021**, 23, 98-107	6.4	0
118	A Tribute to Barrie J. Carter. *Human Gene Therapy*, **2020**, 31, 491-493	4.8	1
117	Site-Directed Mutagenesis Improves the Transduction Efficiency of Capsid Library-Derived Recombinant AAV Vectors. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 545-555	6.4	9
116	Adeno-Associated Virus D-Sequence-Mediated Suppression of Expression of a Human Major Histocompatibility Class II Gene: Implications in the Development of Adeno-Associated Virus Vectors for Modulating Humoral Immune Response. *Human Gene Therapy*, **2020**, 31, 565-574	4.8	2
115	Role of Essential Metal Ions in AAV Vector-Mediated Transduction. *Molecular Therapy - Methods and Clinical Development*, **2020**, 18, 159-166	6.4	1
114	AAV Vectors: Are They Safe?. *Human Gene Therapy*, **2020**, 31, 697-699	4.8	12
113	Enhanced Transduction of Human Hematopoietic Stem Cells by AAV6 Vectors: Implications in Gene Therapy and Genome Editing. *Molecular Therapy - Nucleic Acids*, **2020**, 20, 451-458	10.7	10
112	Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B. *Human Gene Therapy*, **2020**, 31, 1114-1123	4.8	10
111	Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases. *Gastroenterology Clinics of North America*, **2019**, 48, 319-330	4.4	8
110	Chinese Medicine Protein and Peptide in Gene and Cell Therapy. *Current Protein and Peptide Science* , **2019**, 20, 251-264	2.8	1
109	Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors. *Molecular Therapy - Methods and Clinical Development*, **2019**, 12, 248-265	6.4	90
108	Adeno-associated Viral Vectors in Gene Therapy **2018**, 1-8		2
107	Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors. *Human Gene Therapy Methods*, **2017**, 28, 49-59	4.9	11

106	Plasmacytoid and conventional dendritic cells cooperate in crosspriming AAV capsid-specific CD8 T cells. *Blood*, **2017**, 129, 3184-3195	2.2	56
105	AuthorsPResponse to Jesse D. Riordan, Hum Gene Ther 2017;28:375-376; DOI: 10.1089/hum.2017.045. *Human Gene Therapy*, **2017**, 28, 376-377	4.8	1
104	Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models. *Journal of Translational Medicine*, **2017**, 15, 94	8.5	15
103	The hepatocyte-specific HNF4/miR-122 pathway contributes to iron overload-mediated hepatic inflammation. *Blood*, **2017**, 130, 1041-1051	2.2	36
102	AAV Infection: Protection from Cancer. *Human Gene Therapy*, **2017**, 28, 323-327	4.8	25
101	Development of Optimized AAV Serotype Vectors for High-Efficiency Transduction at Further Reduced Doses. *Human Gene Therapy Methods*, **2016**, 27, 143-9	4.9	15
100	High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing. *Scientific Reports*, **2016**, 6, 35495	4.9	23
99	Microglia-specific targeting by novel capsid-modified AAV6 vectors. *Molecular Therapy - Methods and Clinical Development*, **2016**, 3, 16026	6.4	55
98	Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector. *Human Gene Therapy*, **2016**, 27, 1-6	4.8	13
97	Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors. *Molecular Therapy - Methods and Clinical Development*, **2016**, 3, 16029	6.4	17
96	Superior In vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid. *Molecular Therapy*, **2016**, 24, 1042-1049	11.7	65
95	In vivo tissue-tropism of adeno-associated viral vectors. *Current Opinion in Virology*, **2016**, 21, 75-80	7.5	150
94	Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. *Journal of Virology*, **2015**, 89, 952-61	6.6	26
93	Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo. *Human Gene Therapy Methods*, **2015**, 26, 211-20	4.9	21
92	Efficient and Targeted Transduction of Nonhuman Primate Liver With Systemically Delivered Optimized AAV3B Vectors. *Molecular Therapy*, **2015**, 23, 1867-76	11.7	58
91	Review of bioaerosols in indoor environment with special reference to sampling, analysis and control mechanisms. *Environment International*, **2015**, 85, 254-72	12.9	163
90	The Adeno-Associated Virus Genome Packaging Puzzle. *Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research*, **2015**, 9,	2.5	12
89	Prevalence of neutralizing antibodies against liver-tropic adeno-associated virus serotype vectors in 100 healthy Chinese and its potential relation to body constitutions. *Journal of Integrative Medicine*, **2015**, 13, 341-6	4	20

88	Adeno-Associated Virus Type 2 and Hepatocellular Carcinoma?. *Human Gene Therapy*, **2015**, 26, 779-81	4.8	52
87	Productive life cycle of adeno-associated virus serotype 2 in the complete absence of a conventional polyadenylation signal. *Journal of General Virology*, **2015**, 96, 2780-2787	4.9	3
86	AAV3 Capsid Is Superior for In Vivo Gene Transfer to Human Hepatocytes Compared to Serotypes 5 and 8 in a Mouse/Human Chimeric Model. *Blood*, **2015**, 126, 4418-4418	2.2	
85	Pristimerin enhances recombinant adeno-associated virus vector-mediated transgene expression in human cell lines in vitro and murine hepatocytes in vivo. *Journal of Integrative Medicine*, **2014**, 12, 20-34	4	46
84	Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. *Vaccine*, **2014**, 32, 938-43	4.1	15
83	Selective in vivo targeting of human liver tumors by optimized AAV3 vectors in a murine xenograft model. *Human Gene Therapy*, **2014**, 25, 1023-34	4.8	40
82	Cytotoxic genes from traditional Chinese medicine inhibit tumor growth both in vitro and in vivo. *Journal of Integrative Medicine*, **2014**, 12, 483-94	4	70
81	Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo. *Cytotherapy*, **2013**, 15, 986-98	4.8	58
80	Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. *Blood*, **2013**, 121, 2224-33	2.2	119
79	High-efficiency transduction of primary human hematopoietic stem cells and erythroid lineage-restricted expression by optimized AAV6 serotype vectors in vitro and in a murine xenograft model in vivo. *PLoS ONE*, **2013**, 8, e58757	3.7	38
78	Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?. *PLoS ONE*, **2013**, 8, e59142	3.7	67
77	Identification and characterization of size-segregated bioaerosols at Jawaharlal Nehru University, New Delhi. *Natural Hazards*, **2012**, 60, 485-499	3	16
76	High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors. *Vaccine*, **2012**, 30, 3908-17	4.1	34
75	Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation. *Human Gene Therapy Methods*, **2012**, 23, 225-33	4.9	29
74	Role of molecular genetics in hemophilia: from diagnosis to therapy. *Seminars in Thrombosis and Hemostasis*, **2012**, 38, 64-78	5.3	21
73	A simplified immune suppression scheme leads to persistent micro-dystrophin expression in Duchenne muscular dystrophy dogs. *Human Gene Therapy*, **2012**, 23, 202-9	4.8	40
72	Development of Novel Recombinant AAV Vectors and Strategies for the Potential Gene Therapy of Hemophilia. *Journal of Genetic Syndromes & Gene Therapy*, **2012**, S1,		7
71	Cellular fusion for gene delivery to SCA1 affected Purkinje neurons. *Molecular and Cellular Neurosciences*, **2011**, 47, 61-70	4.8	31

70	High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors. *Journal of Visualized Experiments*, **2011**,	1.6	22
69	Innate Immune Responses to AAV Vectors. *Frontiers in Microbiology*, **2011**, 2, 194	5.7	95
68	Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. *Molecular Therapy*, **2011**, 19, 293-301	11.7	196
67	A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo. *Human Gene Therapy*, **2011**, 22, 633-40	4.8	9
66	Enhanced long-term transduction and multilineage engraftment of human hematopoietic stem cells transduced with tyrosine-modified recombinant adeno-associated virus serotype 2. *Human Gene Therapy*, **2010**, 21, 1129-36	4.8	26
65	Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. *Human Gene Therapy*, **2010**, 21, 1741-7	4.8	72
64	High-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapy. *Human Gene Therapy*, **2010**, 21, 1527-43	4.8	60
63	Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. *Human Gene Therapy*, **2010**, 21, 271-83	4.8	30
62	Gene Therapy of Hemoglobinopathies **2010**, 197-212		
61	High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. *Molecular Therapy*, **2010**, 18, 2048-56	11.7	103
60	Adeno-associated virus serotype 6 capsid tyrosine-to-phenylalanine mutations improve gene transfer to skeletal muscle. *Human Gene Therapy*, **2010**, 21, 1343-8	4.8	62
59	An animal model of PDH deficiency using AAV8-siRNA vector-mediated knockdown of pyruvate dehydrogenase E1 *Molecular Genetics and Metabolism*, **2010**, 101, 183-91	3.7	13
58	Two decades of clinical gene therapy--success is finally mounting. *Discovery Medicine*, **2010**, 9, 105-11	2.5	54
57	High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors. *Molecular Therapy*, **2009**, 17, 463-71	11.7	299
56	Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. *Virology*, **2008**, 381, 194-202	3.6	167
55	Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 7827-32	11.5	422
54	Optimization of recombinant adeno-associated viral vectors for human beta-globin gene transfer and transgene expression. *Human Gene Therapy*, **2008**, 19, 365-75	4.8	10
53	Pyruvate dehydrogenase complex deficiency caused by ubiquitination and proteasome-mediated degradation of the E1 subunit. *Journal of Biological Chemistry*, **2008**, 283, 237-243	5.4	27

52	Single-polarity recombinant adeno-associated virus 2 vector-mediated transgene expression in vitro and in vivo: mechanism of transduction. *Molecular Therapy*, **2008**, 16, 290-5	11.7	35
51	Adeno-associated virus-mediated gene transfer. *Journal of Cellular Biochemistry*, **2008**, 105, 17-24	4.7	22
50	A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. *Molecular Therapy*, **2007**, 15, 1323-30	11.7	105
49	Self-complementary recombinant adeno-associated viral vectors: packaging capacity and the role of rep proteins in vector purity. *Human Gene Therapy*, **2007**, 18, 171-82	4.8	73
48	Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. *Virology*, **2006**, 353, 283-93	3.6	59
47	Adeno-associated virus-mediated gene transfer in hematopoietic stem/ progenitor cells as a therapeutic tool. *Current Gene Therapy*, **2006**, 6, 683-98	4.3	20
46	Role of integrin cross-regulation in parvovirus B19 targeting. *Human Gene Therapy*, **2006**, 17, 909-20	4.8	11
45	Evaluation of primitive murine hematopoietic stem and progenitor cell transduction in vitro and in vivo by recombinant adeno-associated virus vector serotypes 1 through 5. *Human Gene Therapy*, **2006**, 17, 321-33	4.8	28
44	Evaluation of Primitive Murine Hematopoietic Stem and Progenitor Cell Transduction In Vitro and In Vivo by Recombinant Adeno-Associated Virus Vector Serotypes 1 Through 5. *Human Gene Therapy*, **2006**, 060125023345001	4.8	
43	Evaluation of Primitive Murine Hematopoietic Stem and Progenitor Cell Transduction In Vitro and In Vivo by Recombinant Adeno-Associated Virus Vector Serotypes 1 Through 5. *Human Gene Therapy*, **2006**, 060301061832003	4.8	
42	Role of Integrin Cross-Regulation in Parvovirus B19 Targeting. *Human Gene Therapy*, **2006**, 060913044654807	4.8	
41	Hematopoietic stem cell transduction by recombinant adeno-associated virus vectors: problems and solutions. *Human Gene Therapy*, **2005**, 16, 792-8	4.8	32
40	Hematopoietic Stem Cell Transduction by Recombinant Adeno-Associated Virus Vectors: Problems and Solutions. *Human Gene Therapy*, **2005**, 050701034702013	4.8	
39	Gene delivery to human and murine primitive hematopoietic stem and progenitor cells by AAV2 vectors. *Methods in Molecular Biology*, **2004**, 246, 245-54	1.4	5
38	Impaired nuclear transport and uncoating limit recombinant adeno-associated virus 2 vector-mediated transduction of primary murine hematopoietic cells. *Human Gene Therapy*, **2004**, 15, 1207-18	4.8	53
37	Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90. *Journal of Biological Chemistry*, **2004**, 279, 12714-23	5.4	37
36	Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo. *Molecular Therapy*, **2004**, 10, 950-7	11.7	39
35	Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines in vitro and transgenic mice in vivo. *Journal of Virology*, **2003**, 77, 2741-6	6.6	53

34	Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. *Blood*, **2003**, 102, 3927-33	2.2	182
33	Obstacles to human hematopoietic stem cell transduction by recombinant adeno-associated virus 2 vectors. *Journal of Cellular Biochemistry*, **2002**, 38, 39-45	4.7	23
32	Recombinant human parvovirus B19 vectors. *Pathologie Et Biologie*, **2002**, 50, 295-306		2
31	Delivery Systems for Gene Therapy: Adeno-Associated Virus 2 **2002**, 257-288		3
30	Infection of purified nuclei by adeno-associated virus 2. *Molecular Therapy*, **2001**, 4, 289-96	11.7	74
29	Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice. *Molecular Therapy*, **2001**, 3, 940-6	11.7	44
28	Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. *Journal of Virology*, **2001**, 75, 8968-76	6.6	113
27	Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. *Journal of Virology*, **2001**, 75, 4110-6	6.6	107
26	Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. *Journal of Virology*, **2001**, 75, 4080-90	6.6	124
25	Gene therapy with viral vectors: the hope, the problems, and the solution. *Journal of Hematotherapy and Stem Cell Research*, **2001**, 10, 321-2		3
24	Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. *Journal of Virology*, **2000**, 74, 992-6	6.6	136
23	Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted expression from parvovirus B19p6 promoter in primary human hematopoietic progenitor cells. *Journal of Hematotherapy and Stem Cell Research*, **1999**, 8, 585-92		16
22	Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. *Nature Medicine*, **1999**, 5, 71-7	50.5	545
21	Adeno-associated virus 2 co-receptors?-first reply. *Nature Medicine*, **1999**, 5, 468-468	50.5	213
20	Parvoviral Vectors for Human Hematopoietic Gene Therapy. *Blood Cell Biochemistry*, **1999**, 89-122		1
19	Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. *Journal of Virology*, **1998**, 72, 9835-43	6.6	80
18	Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. *Journal of Virology*, **1998**, 72, 1593-9	6.6	104
17	Rescue and autonomous replication of adeno-associated virus type 2 genomes containing Rep-binding site mutations in the viral p5 promoter. *Journal of Virology*, **1998**, 72, 4811-8	6.6	17

16	Recombinant human parvovirus B19 vectors: erythroid cell-specific delivery and expression of transduced genes. *Journal of Virology*, **1998**, 72, 5224-30	6.6	45
15	Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. *Journal of Virology*, **1998**, 72, 5472-80	6.6	53
14	Evaluation of recombinant adeno-associated virus as a gene transfer vector for the retina. *Current Eye Research*, **1997**, 16, 949-56	2.9	66
13	Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. *Gene*, **1997**, 190, 203-10	3.8	114
12	Rescue and replication signals of the adeno-associated virus 2 genome. *Journal of Molecular Biology* , **1995**, 250, 573-80	6.5	53
11	Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. *Cancer Chemotherapy and Pharmacology*, **1994**, 34, 63-6	3.5	56
10	Versatile adeno-associated virus 2-based vectors for constructing recombinant virions. *Gene*, **1993**, 124, 257-62	3.8	41
9	Rescue of the adeno-associated virus 2 genome correlates with alterations in DNA-modifying enzymes in human cells. *Intervirology*, **1992**, 33, 109-15	2.5	16
8	Cloning and integration of DNA fragments in human cells via the inverted terminal repeats of the adeno-associated virus 2 genome. *Gene*, **1992**, 119, 265-72	3.8	22
7	Replication of Adenovirus 2 and Adeno-Associated Virus 2 in Young and Senescent Human Diploid Fibroblasts **1990**, 89-107		
6	Augmented nuclease activity during cellular senescence in vitro. *Journal of Cellular Biochemistry*, **1989**, 39, 75-85	4.7	7
5	Rescue and replication of the adeno-associated virus 2 genome in mortal and immortal human cells. *Intervirology*, **1989**, 30, 74-85	2.5	27
4	Replication of the adeno-associated virus DNA termini in vitro. *Intervirology*, **1987**, 27, 138-47	2.5	35
3	The genetics of adeno-associated virus. *Advances in Experimental Medicine and Biology*, **1984**, 179, 151-61	3.6	19
2	Rescue of adeno-associated virus from recombinant plasmids: gene correction within the terminal repeats of AAV. *Cell*, **1983**, 33, 135-43	56.2	263
1	A Dual Role of EGFR Protein Tyrosine Kinase Signaling in Ubiquitination of AAV2 Capsids and Viral Second-strand DNA Synthesis. *Molecular Therapy*,	11.7	2